Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 1
2006 1
2007 1
2008 2
2010 2
2011 1
2012 4
2013 1
2014 3
2015 5
2017 2
2018 1
2019 5
2020 4
2021 4
2022 3
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Gain-of-function mutant p53: history and speculation.
Bargonetti J, Prives C. Bargonetti J, et al. J Mol Cell Biol. 2019 Jul 19;11(7):605-609. doi: 10.1093/jmcb/mjz067. J Mol Cell Biol. 2019. PMID: 31283823 Free PMC article. Review. No abstract available.
Splice variants of MDM2 in oncogenesis.
Rosso M, Okoro DE, Bargonetti J. Rosso M, et al. Among authors: bargonetti j. Subcell Biochem. 2014;85:247-61. doi: 10.1007/978-94-017-9211-0_14. Subcell Biochem. 2014. PMID: 25201199 Review.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: bargonetti j. Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9. Cancer Lett. 2024. PMID: 38199587 Free article.
Multiple roles of the tumor suppressor p53.
Bargonetti J, Manfredi JJ. Bargonetti J, et al. Curr Opin Oncol. 2002 Jan;14(1):86-91. doi: 10.1097/00001622-200201000-00015. Curr Opin Oncol. 2002. PMID: 11790986 Review.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: bargonetti j. bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406. bioRxiv. 2023. PMID: 38076873 Free PMC article. Updated. Preprint.
MDM2-C Functions as an E3 Ubiquitin Ligase.
Kim JY, Lee R, Xiao G, Forbes D, Bargonetti J. Kim JY, et al. Among authors: bargonetti j. Cancer Manag Res. 2020 Aug 24;12:7715-7724. doi: 10.2147/CMAR.S260943. eCollection 2020. Cancer Manag Res. 2020. PMID: 32904724 Free PMC article.
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. Wilson T, et al. Among authors: bargonetti j. Mol Pharm. 2021 Sep 6;18(9):3418-3428. doi: 10.1021/acs.molpharmaceut.1c00323. Epub 2021 Jul 28. Mol Pharm. 2021. PMID: 34318678 Free PMC article.
47 results